Sanofi India growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue−8.7%−12.8%
EBITDA+0.1%−11.3%
Net Income−21.0%−19.3%
EPS (adj.)−21.0%−19.3%
Total Assets−22.2%−15.4%
Total Equity−13.0%−16.3%
Free Cash Flow−3.0%+3.1%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

SANOFI₹2,992.00

Sanofi India Limited

· Pharma & Health
₹ CrorePeersSENORESINNOVACAPPGHLMOREPENLABIOLCPSANOFICONRFDCORCHPHARMAMcap ₹6,882 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue-8.7-12.8
EBITDA+0.1-11.3
Net Income-21.0-19.3
EPS (adj.)-21.0-19.3
Total Assets-22.2-15.4
Total Equity-13.0-16.3
Free Cash Flow-3.0+3.1
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.